Menu

The HHMI Bump

A new study shows a slight citation benefit to authors recently awarded investigator status from the Howard Hughes Medical Institute.

Jan 28, 2014
Bob Grant

WIKIMEDIA, DVORTYGIRLScientific papers published just prior to their authors being awarded a coveted investigator position at the Howard Hughes Medical Institute (HHMI) are cited 12 percent more than expected, according to new research. The citation bump was more pronounced for papers published in new areas of research or in lower-profile journals. The study, published in this month’s issue of Management Science, compared more than 3,600 life science papers written by 424 HHMI investigators to an equal number of papers written by researchers who had not received the honor. “We found that there was an effect of status,” MIT economist Pierre Azoulay, study coauthor, said in a statement.

Azoulay and his collaborators tracked changes in the citation rates of papers before and after one or more of their authors were named HHMI investigators. They found that citations jumped for some of the papers just after their authors joined the HHMI fold.

“You couldn’t tell them [the pairs of papers] apart in terms of citation trajectories, up until the time of the prize,” Azoulay said.

But the effect was more pronounced in some instances. The citation bump was nearly twice as great for papers published in lower-profile journals, and younger researcher/authors, with less robust reputations prior to their HHMI appointments were more likely to experience the benefits of the award. “The effect was much more pronounced when there was more reason to be uncertain about the quality of the science or the scientist before the prize,” Azoulay added.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.